Alimera Sciences to Report Fourth Quarter 2015 Financial Results on March 2, 2016

Loading...
Loading...

ALPHARETTA, Ga., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences ALIM, a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended December 31st, 2015, at the close of the financial markets on March 2, 2016.

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 10:00 AM ET, on March 3, 2016. Please refer to the information below for conference call dial-in information and webcast registration.

Conference date: March 3, 2016, 10:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences Fourth Quarter 2015 Results Call
Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".

About Alimera Sciences
Alimera Sciences ALIM, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com

Contact: COCKRELL GROUP 877.889.1972 investorrelations@thecockrellgroup.com cockrellgroup.com

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...